Latest news and press releases about Aptevo Therapeutics Inc. (APVO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
Price
| Price | $1.72 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.24 |
| EV / EBITDA | 0.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -201.49% |
| Return on Invested Capital | -262.30% |
| Return on Assets | -181.89% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · BCDA · CERO · EPIX · ERNA · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of APVO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks